Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROCRIT 80,000 Units Weekly in Anemic Cancer Patients
NCT00341055Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Jun 2003
- Modality
- Biologic, rProtein (Recombinant Protein)
01
Overview
Phase 3, open-label, single-arm trial of epoetin alfa in anemia, sponsored by Johnson & Johnson. Primary endpoint: Major Hematologic Response. Started Jun 2003; status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00341055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00341055.